{"id":38376,"date":"2025-08-01T16:27:07","date_gmt":"2025-08-01T08:27:07","guid":{"rendered":"https:\/\/flcube.com\/?p=38376"},"modified":"2025-08-01T16:27:08","modified_gmt":"2025-08-01T08:27:08","slug":"neurodawns-subsidiary-receives-nmpa-approval-for-first-lhi-treatment-rk-4-injection","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=38376","title":{"rendered":"Neurodawn&#8217;s Subsidiary Receives NMPA Approval for First LHI Treatment RK-4 Injection"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">China-based Neurodawn Pharmaceutical Co., Ltd.&#8217;s wholly-owned subsidiary, Fuzhou Ningdan Rongkang Biomedical Technology Co., Ltd. (Ningdan Rongkang), announced that its self-developed Class 1 chemical new drug, RK-4 Injection, has received clinical trial approval from China&#8217;s National Medical Products Administration (NMPA) under approval number 2025LP01893. This marks a significant advancement in the treatment of acute large hemispheric infarction (LHI), a condition with substantial unmet clinical needs.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>RK-4 Injection: A Novel Treatment Approach<\/strong><br>RK-4 Injection represents the world&#8217;s first innovative drug for treating LHI via transcranial bone marrow cavity injection. This unique administration route allows the drug to rapidly enter the brain parenchyma and effectively distribute to the lesion site. By bypassing traditional delivery challenges, RK-4 Injection offers a promising new therapeutic option for patients suffering from this severe form of stroke.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Addressing Unmet Clinical Needs<\/strong><br>LHI is characterized by significant disability and mortality due to the lack of effective treatment options. The approval of RK-4 Injection highlights the potential to address this critical gap in clinical care. Ningdan Rongkang&#8217;s commitment to developing innovative solutions for neurological disorders has led to this milestone achievement.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Clinical Development Plans<\/strong><br>Ningdan Rongkang plans to initiate clinical studies for RK-4 Injection shortly. This phase will focus on evaluating the safety and efficacy of the drug in LHI patients, with the goal of advancing toward broader clinical application and potential market approval.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China-based Neurodawn Pharmaceutical Co., Ltd.&#8217;s wholly-owned subsidiary, Fuzhou Ningdan Rongkang Biomedical Technology Co., Ltd. (Ningdan&#8230;<\/p>\n","protected":false},"author":1,"featured_media":38377,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[62,1908,4261],"class_list":["post-38376","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-neurodawn-pharmaceutical","tag-ningdan-rongkang-biomedical-technology"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.8) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Neurodawn&#039;s Subsidiary Receives NMPA Approval for First LHI Treatment RK-4 Injection - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Neurodawn Pharmaceutical Co., Ltd.&#039;s wholly-owned subsidiary, Fuzhou Ningdan Rongkang Biomedical Technology Co., Ltd. (Ningdan Rongkang), announced that its self-developed Class 1 chemical new drug, RK-4 Injection, has received clinical trial approval from China&#039;s National Medical Products Administration (NMPA) under approval number 2025LP01893. This marks a significant advancement in the treatment of acute large hemispheric infarction (LHI), a condition with substantial unmet clinical needs.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=38376\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Neurodawn&#039;s Subsidiary Receives NMPA Approval for First LHI Treatment RK-4 Injection\" \/>\n<meta property=\"og:description\" content=\"China-based Neurodawn Pharmaceutical Co., Ltd.&#039;s wholly-owned subsidiary, Fuzhou Ningdan Rongkang Biomedical Technology Co., Ltd. (Ningdan Rongkang), announced that its self-developed Class 1 chemical new drug, RK-4 Injection, has received clinical trial approval from China&#039;s National Medical Products Administration (NMPA) under approval number 2025LP01893. This marks a significant advancement in the treatment of acute large hemispheric infarction (LHI), a condition with substantial unmet clinical needs.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=38376\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-01T08:27:07+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-01T08:27:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0106.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38376#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38376\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Neurodawn&#8217;s Subsidiary Receives NMPA Approval for First LHI Treatment RK-4 Injection\",\"datePublished\":\"2025-08-01T08:27:07+00:00\",\"dateModified\":\"2025-08-01T08:27:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38376\"},\"wordCount\":243,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38376#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/0106.webp\",\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Neurodawn Pharmaceutical\",\"Ningdan Rongkang Biomedical Technology\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=38376#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38376\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=38376\",\"name\":\"Neurodawn's Subsidiary Receives NMPA Approval for First LHI Treatment RK-4 Injection - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38376#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38376#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/0106.webp\",\"datePublished\":\"2025-08-01T08:27:07+00:00\",\"dateModified\":\"2025-08-01T08:27:08+00:00\",\"description\":\"China-based Neurodawn Pharmaceutical Co., Ltd.'s wholly-owned subsidiary, Fuzhou Ningdan Rongkang Biomedical Technology Co., Ltd. (Ningdan Rongkang), announced that its self-developed Class 1 chemical new drug, RK-4 Injection, has received clinical trial approval from China's National Medical Products Administration (NMPA) under approval number 2025LP01893. This marks a significant advancement in the treatment of acute large hemispheric infarction (LHI), a condition with substantial unmet clinical needs.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38376#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=38376\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38376#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/0106.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/0106.webp\",\"width\":1080,\"height\":608,\"caption\":\"Neurodawn's Subsidiary Receives NMPA Approval for First LHI Treatment RK-4 Injection\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=38376#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Neurodawn&#8217;s Subsidiary Receives NMPA Approval for First LHI Treatment RK-4 Injection\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Neurodawn's Subsidiary Receives NMPA Approval for First LHI Treatment RK-4 Injection - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Neurodawn Pharmaceutical Co., Ltd.'s wholly-owned subsidiary, Fuzhou Ningdan Rongkang Biomedical Technology Co., Ltd. (Ningdan Rongkang), announced that its self-developed Class 1 chemical new drug, RK-4 Injection, has received clinical trial approval from China's National Medical Products Administration (NMPA) under approval number 2025LP01893. This marks a significant advancement in the treatment of acute large hemispheric infarction (LHI), a condition with substantial unmet clinical needs.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=38376","og_locale":"en_US","og_type":"article","og_title":"Neurodawn's Subsidiary Receives NMPA Approval for First LHI Treatment RK-4 Injection","og_description":"China-based Neurodawn Pharmaceutical Co., Ltd.'s wholly-owned subsidiary, Fuzhou Ningdan Rongkang Biomedical Technology Co., Ltd. (Ningdan Rongkang), announced that its self-developed Class 1 chemical new drug, RK-4 Injection, has received clinical trial approval from China's National Medical Products Administration (NMPA) under approval number 2025LP01893. This marks a significant advancement in the treatment of acute large hemispheric infarction (LHI), a condition with substantial unmet clinical needs.","og_url":"https:\/\/flcube.com\/?p=38376","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-08-01T08:27:07+00:00","article_modified_time":"2025-08-01T08:27:08+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0106.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=38376#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=38376"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Neurodawn&#8217;s Subsidiary Receives NMPA Approval for First LHI Treatment RK-4 Injection","datePublished":"2025-08-01T08:27:07+00:00","dateModified":"2025-08-01T08:27:08+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=38376"},"wordCount":243,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=38376#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0106.webp","keywords":["Clinical trial approval \/ initiation","Neurodawn Pharmaceutical","Ningdan Rongkang Biomedical Technology"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=38376#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=38376","url":"https:\/\/flcube.com\/?p=38376","name":"Neurodawn's Subsidiary Receives NMPA Approval for First LHI Treatment RK-4 Injection - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=38376#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=38376#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0106.webp","datePublished":"2025-08-01T08:27:07+00:00","dateModified":"2025-08-01T08:27:08+00:00","description":"China-based Neurodawn Pharmaceutical Co., Ltd.'s wholly-owned subsidiary, Fuzhou Ningdan Rongkang Biomedical Technology Co., Ltd. (Ningdan Rongkang), announced that its self-developed Class 1 chemical new drug, RK-4 Injection, has received clinical trial approval from China's National Medical Products Administration (NMPA) under approval number 2025LP01893. This marks a significant advancement in the treatment of acute large hemispheric infarction (LHI), a condition with substantial unmet clinical needs.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=38376#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=38376"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=38376#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0106.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0106.webp","width":1080,"height":608,"caption":"Neurodawn's Subsidiary Receives NMPA Approval for First LHI Treatment RK-4 Injection"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=38376#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Neurodawn&#8217;s Subsidiary Receives NMPA Approval for First LHI Treatment RK-4 Injection"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/0106.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38376","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=38376"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38376\/revisions"}],"predecessor-version":[{"id":38378,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/38376\/revisions\/38378"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/38377"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=38376"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=38376"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=38376"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}